(Bloomberg) -- India’s benchmark equity index closed little changed, after fluctuating between gains and losses, as a steady increase in new coronavirus cases slowed the buying spree led by vaccine approvals.
The S&P BSE Sensex rose less than 0.1% to 44,632.65 in Mumbai, while the NSE Nifty 50 Index climbed 0.2% to a new high. Both indexes had climbed as much as 0.8% earlier in the day.
Foreign net equity purchases of $16.6 billion this year through Dec. 1 are already the most since 2013 as funds have poured into emerging markets chasing returns. The relative strength index on both the Sensex and Nifty is around 70, a level that some traders read as a signal that they’re overbought.
“If the vaccine works to a decent level, more money will flow to emerging markets,” said Sameer Kalra, a strategist at Target Investing in Mumbai. “We are now seeing stocks, like banks and industrials, starting to catch up after under performing the market.”
Measures of mid and small-cap stocks climbed for a fifth consecutive session, headed for their first annual gains in three years.
India’s central bank will probably keep interest rates unchanged on Friday for a third straight meeting, based on estimates by economists in a Bloomberg survey. Inflation remains elevated in Asia’s third-largest economy due to supply constraints, while economic growth is showing signs of resuming.
The rupee weakened 0.2% to 73.9263 per U.S. dollar, while the yield on the 10-year government bond rose one basis point to 5.93%.
The Numbers
- Fourteen of 19 sector indexes compiled by BSE Ltd. rose, led by a gauge of metal companies
- Maruti Suzuki India Ltd. contributed the most to the Sensex gain and had the largest move, increasing 7.5%
- HDFC Bank Ltd. was the biggest drag on the index and had the biggest drop, declining 2.1% after the Reserve Bank of India ordered to curb some digital and credit card operations following a series of glitches at the Indian lender
Market-related stories
- Indian Central Bank to Hold Rates Amid Inflation: Decision Guide
- Serum Vaccine Likely in Open Market Post March-April: ET
©2020 Bloomberg L.P.
RECOMMENDED FOR YOU
POPULAR